| 4001 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
26 |
| 4002 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
56 |
| 4003 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
63 |
| 4004 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
61 |
| 4005 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
70 |
| 4006 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
66 |
| 4007 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
48 |
| 4008 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
58 |
| 4009 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
59 |
| 4010 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
62 |
| 4011 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
63 |
| 4012 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
64 |
| 4013 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
66 |
| 4014 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
65 |
| 4015 |
Apheresis |
Allogeneic
|
Myelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
56 |
| 4016 |
Apheresis |
Allogeneic
|
Myelofibrosis With Myeloid Metaplasia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
75 |
| 4017 |
Apheresis |
Allogeneic
|
Myelofibrosis With Myeloid Metaplasia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
65 |
| 4018 |
Apheresis |
Allogeneic
|
Myelofibrosis With Myeloid Metaplasia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
51 |
| 4019 |
Apheresis |
Allogeneic
|
Myelofibrosis With Myeloid Metaplasia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
63 |
| 4020 |
Apheresis |
Allogeneic
|
Myelofibrosis With Myeloid Metaplasia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
75 |
| 4021 |
Apheresis |
Allogeneic
|
Myelofibrosis With Myeloid Metaplasia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
64 |
| 4022 |
Apheresis |
Allogeneic
|
Myeloma Multiplex
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
48 |
| 4023 |
Apheresis |
Allogeneic
|
Myeloma Multiplex
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
53 |
| 4024 |
Apheresis |
Allogeneic
|
Myeloproliferative Neoplasms
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
67 |
| 4025 |
Apheresis |
Allogeneic
|
Myeloproliferative Neoplasms
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
58 |
| 4026 |
Apheresis |
Allogeneic
|
Myeloproliferative Neoplasms
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
51 |
| 4027 |
Apheresis |
Allogeneic
|
No Data
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
64 |
| 4028 |
Apheresis |
Allogeneic
|
No Data
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
57 |
| 4029 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
30 |
| 4030 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
51 |
| 4031 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
58 |
| 4032 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
56 |
| 4033 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
58 |
| 4034 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
50 |
| 4035 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
53 |
| 4036 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
20 |
| 4037 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
64 |
| 4038 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
66 |
| 4039 |
Apheresis |
Allogeneic
|
Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
62 |
| 4040 |
Apheresis |
Autologous
|
Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
61 |
| 4041 |
Apheresis |
Autologous
|
Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
49 |
| 4042 |
Apheresis |
Allogeneic
|
Non-Hodgkin-Lymphoma-Relapse
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
62 |
| 4043 |
Apheresis |
Allogeneic
|
Osteomyelitis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
47 |
| 4044 |
Apheresis |
Allogeneic
|
Osteomyelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
69 |
| 4045 |
Apheresis |
Allogeneic
|
Osteomyelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
43 |
| 4046 |
Apheresis |
Autologous
|
Osteosclerotic Myeloma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
54 |
| 4047 |
Apheresis |
Allogeneic
|
Other Myelodysplastic Syndromes
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
65 |
| 4048 |
Apheresis |
Allogeneic
|
Other Myelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
68 |
| 4049 |
Apheresis |
Allogeneic
|
Other Myelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
70 |
| 4050 |
Apheresis |
Allogeneic
|
Other Myelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
72 |
| 4051 |
Apheresis |
Allogeneic
|
Other Plasma Cell Disorder
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
67 |
| 4052 |
Apheresis |
Allogeneic
|
Peripheral T-Cell Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
45 |
| 4053 |
Apheresis |
Allogeneic
|
Philadelphia-Positive Acute Lymphoblastic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
61 |
| 4054 |
Apheresis |
Allogeneic
|
Polycythemia Vera
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
65 |
| 4055 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
71 |
| 4056 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
66 |
| 4057 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
62 |
| 4058 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
53 |
| 4059 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
44 |
| 4060 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
54 |
| 4061 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
65 |
| 4062 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
65 |
| 4063 |
Apheresis |
Autologous
|
Primary Central Nervous System Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
60 |
| 4064 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
66 |
| 4065 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
63 |
| 4066 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
62 |
| 4067 |
Apheresis |
Allogeneic
|
Primary Myelofibrosis
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
64 |
| 4068 |
Apheresis |
Allogeneic
|
Prolymphocytic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
68 |
| 4069 |
Apheresis |
Allogeneic
|
Prolymphocytic Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
64 |
| 4070 |
Apheresis |
Allogeneic
|
Refractory Cytopenia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
6 |
| 4071 |
Apheresis |
Allogeneic
|
Secondary Acute Lymphoblastic Leukemia From Chronic Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
58 |
| 4072 |
Apheresis |
Allogeneic
|
Secondary Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
70 |
| 4073 |
Apheresis |
Allogeneic
|
Secondary Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
64 |
| 4074 |
Apheresis |
Allogeneic
|
Secondary Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
39 |
| 4075 |
Apheresis |
Allogeneic
|
Secondary Acute Myeloid Leukemia
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
60 |
| 4076 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
35 |
| 4077 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
58 |
| 4078 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
41 |
| 4079 |
Apheresis |
Allogeneic
|
Severe Aplastic Anemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
38 |
| 4080 |
Apheresis |
Allogeneic
|
Severe Combined Immunodeficiency
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
1 |
| 4081 |
Apheresis |
Allogeneic
|
Severe Combined Immunodeficiency
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
1 |
| 4082 |
Apheresis |
Allogeneic
|
T-Cell Lymphoblastic Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
26 |
| 4083 |
Apheresis |
Allogeneic
|
T-Cell Lymphoblastic Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
37 |
| 4084 |
Apheresis |
Autologous
|
T-Cell Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
54 |
| 4085 |
Apheresis |
Autologous
|
T-Cell Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
66 |
| 4086 |
Apheresis |
Autologous
|
T-Cell Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
66 |
| 4087 |
Apheresis |
Autologous
|
T-Cell Non-Hodgkin Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
29 |
| 4088 |
Apheresis |
Allogeneic
|
T-Cell-Lymphoma
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
45 |
| 4089 |
Apheresis |
Autologous
|
Testicular Cancer
|
Hematology
|
2021
|
Standard Therapy
|
Germany
|
33 |
| 4090 |
Apheresis |
Allogeneic
|
Β – Thalassemia
|
Hematology
|
2021
|
Standard Therapy
|
Poland
|
17 |
| 4091 |
Adipose Tissue |
Autologous
|
Gonarthrosis
|
Orthopedy
|
2021
|
Experimental Therapy
|
Poland
|
51 |
| 4092 |
Adipose Tissue |
Autologous
|
Gonarthrosis
|
Orthopedy
|
2021
|
Experimental Therapy
|
Poland
|
44 |
| 4093 |
Adipose Tissue |
Autologous
|
Gonarthrosis
|
Orthopedy
|
2021
|
Experimental Therapy
|
Poland
|
35 |
| 4094 |
Adipose Tissue |
Autologous
|
Internal Damage To The Knee Joint
|
Orthopedy
|
2021
|
Experimental Therapy
|
Poland
|
41 |
| 4095 |
Adipose Tissue |
Autologous
|
Soft Tissue Diseases Related To Use, Overload And Pressure
|
Orthopedy
|
2021
|
Experimental Therapy
|
Poland
|
27 |
| 4096 |
Placenta blood |
Autologous
|
Cerebral Palsy
|
Neurology
|
2020
|
Experimental Therapy
|
Poland
|
2 |
| 4097 |
Cord Tissue |
Allogeneic – Unrelated
|
Covid-19
|
Pulmonology
|
2020
|
Experimental Therapy
|
Poland
|
84 |
| 4098 |
Cord Tissue |
Allogeneic – Unrelated
|
Acquired Epileptic Aphasia
|
Neurology
|
2020
|
Experimental Therapy
|
Poland
|
4 |
| 4099 |
Cord Tissue |
Allogeneic – Unrelated
|
Acute Graft Versus Host Disease
|
Hematology
|
2020
|
Experimental Therapy
|
Poland
|
8 |
| 4100 |
Cord Tissue |
Allogeneic – Unrelated
|
Acute Graft Versus Host Disease
|
Hematology
|
2020
|
Experimental Therapy
|
Poland
|
8 |